Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-versus-Host Disease

Web Exclusives - FDA Approvals, Select Drug Profiles

On July 16, 2021, the FDA accelerated the approval of belumosudil (Rezurock; Kadmon Pharmaceuticals), an oral kinase inhibitor, for the treatment of patients aged ≥12 years with chronic graft-versus-host disease (GVHD) who have received ≥2 lines of systemic therapy. Belumosudil was granted a breakthrough therapy designation for this indication.

“Rezurock represents a new treatment paradigm for thousands of chronic GVHD patients, including those with difficult-to-treat manifestations like fibrosis,” said Corey Cutler, MD, MPH, FRCPC, Associate Professor of Medicine, Harvard Medical School, and Medical Director, Adult Stem Cell Transplantation Program, Dana-Farber Cancer Institute, Boston. “Rezurock has shown robust and durable responses across the spectrum of chronic GVHD, and is safe and well-tolerated.”

Belumosudil was approved based on the KD025-213 study, a randomized, open-label, multicenter dose-ranging clinical trial of 65 patients with chronic GVHD who received belumosudil 200 mg once daily. The main efficacy measure was overall response rate (ORR) through cycle 7 of day 1.

The ORR was 75% (95% confidence interval, 63%-85%), which included 6% complete responses and 69% partial responses. The median time to first response was 1.8 months. The median duration of response was 1.9 months. Among the patients who achieved a response, no death or new systemic therapy initiation occurred in 62% of the patients for at least 12 months since the response.

The most common (≥20%) adverse events were infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension.

Related Items
Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation
June 2023 Vol 16, No 1 published on June 2, 2023 in FDA Approvals
Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
June 2023 Vol 16, No 1 published on June 2, 2023 in FDA Approvals
Polivy Receives New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma
June 2023 Vol 16, No 1 published on June 2, 2023 in FDA Approvals
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
Web Exclusives published on December 14, 2022 in FDA Approvals
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
Web Exclusives published on December 7, 2022 in FDA Approvals
Last modified: November 2, 2021
© Amplity Health. All rights reserved.